(Q35127410)

6 August 2017

1 reference

title

Inflammation and coagulation: implications for the septic patient (English)

1 reference

6 August 2017

Inflammation and Coagulation: Implications for the Septic Patient (English)

1 reference

2 January 2024

0 references

R. Phillip Dellinger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746771

2 January 2024

language of work or name

English

0 references

publication date

8 May 2003

1 reference

Clinical Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

36

1 reference

6 August 2017

issue

10

1 reference

6 August 2017

page(s)

1259-1265

1 reference

The endothelium in sepsis: source of and a target for inflammation

6 August 2017

cites work

1 reference

Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis

21 January 2018

1 reference

Endothelial cell dysfunction and coagulation

21 January 2018

1 reference

Filgrastim in patients with pneumonia and severe sepsis or septic shock

21 January 2018

1 reference

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

21 January 2018

1 reference

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

From mega to more reasonable doses of corticosteroids: a decade to recreate hope

21 January 2018

1 reference

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

21 January 2018

1 reference

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

Immunomodulatory therapies in sepsis

21 January 2018

1 reference

Combined procoagulant and innate immune responses to infection: toward more potent drugs in septic patients

21 January 2018

1 reference

Does inflammation contribute to thrombotic events?

21 January 2018

1 reference

Vascular-bed--specific hemostasis and hypercoagulable states

21 January 2018

1 reference

Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms

21 January 2018

1 reference

The sepsis syndrome. Definition and general approach to management

21 January 2018

1 reference

Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome

21 January 2018

1 reference

Tissue factor in experimental acute lung injury

21 January 2018

1 reference

Phylogenetic and functional relationships between coagulation and the innate immune response

21 January 2018

1 reference

Low levels of protein C are associated with poor outcome in severe sepsis

21 January 2018

1 reference

Tissue factor pathway of coagulation in sepsis

21 January 2018

1 reference

Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis

21 January 2018

1 reference

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

21 January 2018

1 reference

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

21 January 2018

1 reference

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

21 January 2018

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

21 January 2018

1 reference

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

Sir Isaac Newton, sepsis, SIRS, and CARS

21 January 2018

1

1 reference

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

2 January 2024

2

1 reference

Alterations in coagulation and fibrinolysis during sepsis.

2 January 2024

7

1 reference

The role of tumor necrosis factor in the development of multiple organ failure in a murine model

2 January 2024

8

1 reference

Pretreatment with tumor necrosis factor-alpha attenuates arterial hypotension and mortality induced by endotoxin in pigs

2 January 2024

9

1 reference

The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats

2 January 2024

10

1 reference

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

2 January 2024

12

1 reference

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

2 January 2024

15

1 reference

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

2 January 2024

16

1 reference

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

2 January 2024

20

1 reference

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

2 January 2024

21

1 reference

Corticosteroids for patients with septic shock

2 January 2024

23

1 reference

Corticosteroids for patients with septic shock

2 January 2024

24

1 reference

Role of NFkappaB in the mortality of sepsis

2 January 2024

26

1 reference

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

2 January 2024

27

1 reference

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

2 January 2024

31

1 reference

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

2 January 2024

32

1 reference

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

2 January 2024

33

1 reference

The Journal of critical illness

2 January 2024

34

9

51

Carvalho AC

1994

1 reference

Dear SIRS, I'm sorry to say that I don't like you

2 January 2024

36

1 reference

Sepsis: a new hypothesis for pathogenesis of the disease process

2 January 2024

38

1 reference

Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex

2 January 2024

46

1 reference

2 January 2024

The protein C pathway

47

1 reference

In situ ischemia and hypoxia enhance alveolar macrophage tissue factor expression

2 January 2024

49

1 reference

Coagulation abnormalities in acute lung injury and sepsis

2 January 2024

51

1 reference

Roundtable I: relationships between coagulation and inflammatory processes

2 January 2024

53

1 reference

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

2 January 2024

54

1 reference

Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats

2 January 2024

58

1 reference

American Journal of Physiology

2 January 2024

63

270

L921

Uchiba M

1996

1 reference

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

2 January 2024

70

1 reference

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

2 January 2024

72

1 reference

2 January 2024

Identifiers

DOI

10.1086/374835

1 reference

6 August 2017

1 reference